Company / SG&A Expense
Charles River Laboratories SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$743.1M
FY2025
5-year range
$517.6M / $751.0M
FY2021-FY2025
Trend
-1.1%
vs FY2024
Sector context
#54 of 158
Health Care
What the data says
At $743M, Charles River Laboratories's sg&a expense ranks #105 of 158 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $365M in FY2016 to $751M in FY2024.
Based on SEC 10-K filings.
$743M in FY2025 with a 5-year CAGR of +10.9%.
Increased from $620M to $743M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +12.0%
- 5-Year CAGR
- +10.9%
- 10-Year CAGR
- -
Sector benchmark
#105 of 158 in Health CareTop 66% of 158This company $743.1M Sector average $175.9B
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.9%, indicating consistent growth.
- In FY2025, sg&a expense decreased 1.1% year-over-year.
- Ranks #54 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $743.1M | -1.1% |
| FY2024 | $751.0M | +21.1% |
| FY2023 | $619.9M | +17.2% |
| FY2022 | $528.9M | +2.2% |
| FY2021 | $517.6M | +16.6% |
| FY2020 | $443.9M | +19.6% |
| FY2019 | $371.3M | -16.4% |
| FY2018 | $443.9M | +19.6% |
| FY2017 | $371.3M | +1.8% |
| FY2016 | $364.7M | +61.6% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026